NN 9101Alternative Names: NN9101
Latest Information Update: 04 Feb 2010
At a glance
- Originator Novo Nordisk
- Mechanism of Action Glucokinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 04 Feb 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (unspecified route)
- 13 Jun 2006 Phase-I clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route)